What You Should Know:
– Senseonics Holdings, a medical technology company specializing in implantable continuous glucose monitoring (CGM) systems, has announced a Memorandum of Understanding (MOU) with Ascensia Diabetes Care to transition all global commercialization and distribution of its Eversense 365 and future products to Senseonics. Since 2020, Ascensia, a member of PHC Group, has held the exclusive worldwide distribution rights for Eversense products.
This strategic move is set to take effect in the U.S. on January 1, 2026, with Senseonics assuming responsibility for all global sales, marketing, and commercialization. Brian Hansen, who has served as President of CGM at Ascensia, will join Senseonics as Chief Commercial Officer on the same day.
A Strategic Shift for Accelerated Growth
Eversense 365 is the world’s first and only year-long continuous glucose monitor. According to Tim Goodnow, PhD, President and CEO of Senseonics, the go-to-market approach for Eversense is diverging from Ascensia’s core business, and the product is at an inflection point that requires fully dedicated commercial efforts and tight vertical integration. By bringing commercialization in-house, the company believes it can achieve accelerated growth and realize the product’s full potential faster than under the current structure.
Financial Outlook and Operational Benefits
The planned transition is expected to position Senseonics to better meet the needs of payers, providers, and patients, while also improving efficiency and agility. Owning the commercial channel is also expected to increase Senseonics’s topline revenue and expand margins by eliminating the revenue sharing with Ascensia.
Senseonics expects to see immediate revenue improvement and a gross margin expansion to 50% in 2026, with a planned increase to more than 70% gross margins at scale. These investments in the commercial organization would be funded in part by the improved margins, as well as from an expanded $100 million non-dilutive debt facility with Hercules Capital, Inc..
Senseonics continues to expect full-year 2025 global net revenue to be approximately $34-38M. This outlook assumes a doubling of the global patient base during 2025, with two-thirds of the revenue generated in the second half of the year. Full-year 2025 gross margins are expected to be between 32.5% and 37.5%, with cash used in operations projected to be approximately $60M.
